The Slamburger™ Hangover Helper - Order the Slamburger™ - a juicy burger, topped with hash browns, an egg, crispy Applewood ...
MCLEAN, Va., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Freddie Mac (OTCQB: FMCC) today released the results of its Primary Mortgage ...
SANTA CLARA, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Silvaco Group, Inc. (Nasdaq: SVCO) ("Silvaco"), a provider of TCAD, EDA software and SIP solutions that enable semiconductor design and digital ...
Nasdaq Staff determined that for the 10 consecutive business days between December 4, 2024 to December 17, 2024, the closing bid price of the Company’s Class A ordinary shares has been at $1.00 per ...
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic testing and precision medicine, announced that a MyRisk ® Hereditary Cancer Test with RiskScore ® study has been named in the ...
Under the share repurchase program, the shares may be repurchased from time to time using a variety of methods, which may include open market transactions, privately negotiated transactions or ...
AUSTIN, Texas, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the ...
SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of ...
TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Timbercreek Financial (TSX: TF) (the “Company”) is pleased to announce that it has declared a monthly cash dividend of $0.0575 per common share (“Common ...
WAUWATOSA, Wis., Dec. 19, 2024 (GLOBE NEWSWIRE) -- On December 19, 2024, the Board of Directors of Waterstone Financial, Inc. (NASDAQ: WSBF) declared a regular quarterly cash dividend of $0.15 per ...
Seacoast Banking Corporation of Florida (“Seacoast” or the “Company”) (NASDAQ: SBCF) announced that on December 18, 2024, its Board of Directors (the “Board”) renewed the Company's share repurchase ...
NOVATO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), today announced that the first patient has been dosed in the pivotal Phase 3 Aspire study ( NCT06617429 ...